Ersilia is a nonprofit initiative that supports research against infectious and neglected diseases. Our goal is to facilitate the adoption of artificial intelligence tools to accelerate the development of new medicines. We focus on establishing collaborations in low-resourced settings, where drug discovery costs are prohibitive.

Open-source drug discovery for global health

“To truly tackle healthcare problems, all countries need to be producers of research as well as consumers of it.” — WHO

Disease Burden

In LMICs, infectious diseases are still accountable for up to 60% of the disease burden.

Antimicrobial Drugs

Less than 15% of the drugs currently in development are targeting infectious diseases.

Scientifc Output

LMICs produce only 9% of science and engineering papers.

Our team merges expertise in chemistry, molecular biology and computational pharmacology with a natural enthusiasm for global health. We believe in open-source science as a means to generate low revenue drugs and thus contribute to a more egalitarian world.

Edoardo Gaude
Trustee and co-founder

Edoardo is motivated in making an impact by applying his expertise to real-world medical needs. After a PhD in oncology at the University of Cambridge, Edoardo took on a clinical scientist position at Owlstone Medical Ltd (Cambridge, UK). In 2018, he founded POCKiT diagnostics Ltd, a medical company aimed at improving stroke care. During his academic and industrial career, he published ~40 scientific articles, filed 3 patents, designed and performed several clinical studies, and contributed to raising £1.2M public and private funds. With Ersilia, Edoardo aims to harness his science entrepreneurship expertise for the creation and furthering of open innovation and science crowdsourcing.

Learn more

Miquel Duran
CSO and co-founder

Miquel’s research interests lay at the intersection between drug discovery and large-scale biological data analysis. During his PhD studies and early career, Miquel developed several in silico methods, producing scientific publications in a broad range of topics, from theoretical chemistry to cell-based data. Along this process, he has worked at IRB Barcelona, the Massachusetts Institute of Technology (MIT), Tel Aviv University, ISGlobal-CISM (Mozambique) and CIDRZ (Zambia). With Ersilia, Miquel aims to apply his expertise in computational pharmacology to unmet clinical needs of the Global South.

Learn more

Gemma Turon
Project Manager and co-founder

Trained as a molecular biologist, Gemma completed a PhD in colorectal cancer and stem cells at IRB Barcelona. Her interests, though, span a broad range of topics, with a special interest in global health and neglected diseases. This led her to move, recently, to Zambia and Palestine, to cooperate with local social circus NGOs, her other passion. These stays have given her insight on how to work and implement programs in emerging economies. With Ersilia, Gemma hopes to bring together her scientific knowledge and her social work to deliver high-quality, fast services that will effectively tackle some of the most urgent health issues in developing countries.

Learn more

We are on a mission to build the largest collection of ready-to-use AI models for drug discovery. We collect the latest advances from the scientific literature and develop tailor-made tools in collaboration with researchers worldwide.

A hub of artificial intelligence models

Ersilia technology is data-driven and achieves state-of-the-art performance thanks to the integration of chemical, genomic and biomedical text data. Our AI tools are trained on millions of data points collected from the scientific literature and are available at no cost.

Unlike conventional methods, Ersilia builds upon bioactivity signatures, a richer representation of molecules. Bioactivity signatures embed the available experimental data for every compound, including their targets and side-effects profiles, and are thus more powerful and clinically relevant predictors of bioactivity.

Researchers interested in a specific disease, target or pathogen can use our tools to prioritize drug candidates. The way around is also true. Given a drug of interest, Ersilia will scope for potential indications, mechanisms of action or toxicities.

Open Source

Our goal is to democratize drug discovery by providing a user-friendly, transparent resource available to everyone.

Global Reach

We empower research where medical care is most needed by fostering collaborations with health organizations in low and middle-income countries.

Predictive Models

We illuminate neglected regions of the chemical space to enable drug repurposing, hit-to-lead optimisation and generation of new molecules.

We endorse the principles of Open Science. Our activities are nonprofit, transparent and collaborative.